Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
World Vitiligo Map
Your guide to the vitiligo community worldwide. Use the selector to filter by patient support groups, specialists, research centers, clinical trial locations, or World Vitiligo Day events.
Directory Information & Disclaimer
This free public directory gathers information from public sources to help connect our global community. Medical professionals and organizations listed are independent and not affiliated with or endorsed by the Vitiligo Research Foundation (VRF), and no fees are accepted for listings.
Because clinics, support groups, and specialists move or update their services over time, some information may occasionally become outdated. As a result, VRF cannot guarantee the complete accuracy or usefulness of listed third-party resources.
Help Us Keep the Map Accurate
Do you need to add a listing, update outdated details, or request a removal? Please reach out to us using the feedback form on our Contact Us page.
Search Map
70 records found for “NCT07431177” · show all
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoBellaire Dermatology Associates, Bellaire, Texas, 77401, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoCenter for Clinical Studies, Houston, Texas, 77030, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoAustin Inst for Clinical Research, Pflugerville, Texas, 78660, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoVirginia Clinical Research, Norfolk, Virginia, 23507, United States
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Sydney, New South Wales, 2010, Australia
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Waitara, New South Wales, 2077, Australia
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Melbourne, Victoria, 3000, Australia
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Calgary, Alberta, T2J 7E1, Canada
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Mississauga, Ontario, L4Y 4C5, Canada
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Québec, Quebec, G1V 4X7, Canada
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Guangzhou, Guangdong, 510091, China
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Wuhan, Hubei, 430022, China
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Beijing, 100050, China
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Shanghai, 200040, China
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Brest, 29609, France
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Créteil, 94010, France
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Nice, 06202, France
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Rouen, 76031, France
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Toulouse, 31400, France
1-888-669-6682
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Phase: PHASE2
Intervention: Drug: GIA632; Drug: Placebo
Status: Open now
Organizer: Novartis Pharmaceuticals
Trial page: https://vrfoundation.org/trials/gia632-antibody-treatment-for-nonsegmental-vitiligoNovartis Investigative Site, Bielefeld, 33647, Germany
1-888-669-6682
FAQOther Questions
- Will it spread?
Vitiligo is famously unpredictable, but it doesn't move at random. By looking at thousands of cases, researchers have identified specific patterns of how the condition behaves. ...
- Is there a traditional medicine to treat vitiligo?
Traditional remedies can be helpful for managing stress or general metabolic health, but when it comes to vitiligo, the evidence is limited. While some natural supplements provi...
- Vitiligo and Pregnancy
Pregnancy with vitiligo? The good news: vitiligo itself doesn’t make pregnancy unsafe. Most women stay stable (some even improve), though flares can pop up after birth — usually...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.